BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2008

View Archived Issues

Abbott identifies novel Tie-2 inhibitors active against cancer in preclinical studies

Read More

Trial demonstrates immunomodulating effects of COLD-fX

Read More

Medtronic commences U.S. and international Endeavor Resolute stent trials

Read More

Invitrogen and Biocare to market FDA approved SPOT-Light HER2 CISH Kit

Read More

Odanacatib suppresses bone resorption in breast cancer with established bone metastases

Read More

Threshold begins phase I/II study for TH-302 in patients with soft tissue sarcoma

Read More

Temoporfin improves tumoricidal depth in photodynamic therapy for bile duct cancer

Read More

Long-term safety for Diamyd vaccination in phase II autoimmune diabetes study

Read More

GSK and XenoPort submit NDA to FDA for Solzira in restless legs syndrome

Read More

Novavax tests seasonal influenza VLP vaccine candidate in phase II trial

Read More

Neuropharma changes name to Noscira, announces completion of phase I trials of NP-12

Read More

Priority review for Coartem

Read More

Compugen discovers peptide drug candidate for treatment of solid tumors

Read More

New therapeutic agents for HCV infection disclosed in recent patents

Read More

Recent patents report novel analgesic agents

Read More

New anti-HIV agents described in recent Myriad and Novartis patents

Read More

Mymetics achieves successful results in mucosal HIV/AIDS vaccine viral challenge

Read More

Myriad presents top-line results from phase I Vivecon trial

Read More

Clinical results of PANVAC-VF in metastatic breast cancer reported

Read More

China Biologic receives SFDA approval for human coagulation factor VIII trial

Read More

Depomed initiates phase III program for Gabapentin GR in menopausal hot flashes

Read More

DXL-625 shows superiority to Rituxan in animal studies

Read More

FDA approves expanded uses for Gardasil

Read More

Oramed initiates GLP1 analogue program with ORMD-0901

Read More

Davanat data filed for registration in late-stage colorectal cancer

Read More

Merck Serono commences ORACLE MS trial to evaluate Cladribine in MS

Read More

S*BIO initiates U.S. phase I trials of oral JAK2 inhibitor SB-1518

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing